Article content
Health Canada has approved its third COVID-19 vaccine, authorizing the jab made by AstraZeneca and Oxford University after a lengthy review of clinical trial details.
AstraZeneca was the first to apply for approval in Canadalast October and was greenlit earlier in many jurisdictions including the United Kingdom, Mexico, India, and the entire European Union.
But Health Canada sought further data from the company before authorizing the new vaccine on Friday.
Heres what we know about the AstraZeneca product:
WHY DID IT TAKE SO LONG TO APPROVE?
Health Canadas regulatory team had been reviewing AstraZenecas application since Oct. 1, 2020, and was undergoing its final assessment of clinical data as of late last month.
Dr. Supriya Sharma, Health Canadas chief medical adviser, said in January the review was a bit more complicated because some volunteers in AstraZenecas trials only received a half dose at first.
HOW EFFECTIVE WAS THE VACCINE IN CLINICAL TRIALS?
Data released by the company suggested the vaccine was 62 per cent effective in clinical trials when two full doses were distributed a month apart. Another dosing regimen, where a half dose was followed by a full dose 28 days later, was shown in interim data to be 90 per cent effective.
Advertisement
This advertisement has not loaded yet, but your article continues below.
Article content
Sharma says the recommendations are to administer two shots with the same dosage amount four to 12 weeks apart. She added there was some limited data suggesting a better immune response was observed when the second dose was given closer to the 12-week range.
AstraZenecas efficacy compares with the 95 per cent efficacy from the clinical trials of Pfizer-BioNTech and Moderna, the other two vaccines currently approved in Canada.
Preliminary results from AstraZenecas trial were reviewed early on by The Lancet medical journal, which suggested the vaccine can reduce spread of the virus as well as protect against illness and death.
Health Canada says that while the vaccine was not tested on people over the age of 65, real-world data from countries already using the product suggest it is safe and effective among older age groups.
Sharma noted that while the efficacy ranged with the three approved vaccines, all of them saw zero hospitalizations and deaths in those who got COVID after getting the vaccine.
DOES IT WORK AGAINST THE NEW VARIANTS?
A group of experts on immunization working with the World Health Organization is recommending the use of AstraZenecas vaccine, even in countries where variants emerged as dominant.
That guidance comes after a small study in South Africa suggested AstraZenecas vaccine was only minimally effective against the variant first detected there, causing the country to halt use of the product earlier this month.
Advertisement
This advertisement has not loaded yet, but your article continues below.
Article content
South Africa said it would instead give the still-unapproved Johnson and Johnson vaccine to front-line health workers to see how it protects against the more contagious variant thats dominant there.
Oxford University, who helped develop the AstraZeneca vaccine, has said researchers were tweaking their product by inserting a genetic sequence from that specific variant.
AstraZenecas vaccine has some promising early data suggesting it works against another variant first detected in the U.K. Findings based on swabs taken from around 500 volunteers in trials between October and January showed a 74.6 per cent efficacy rate against that variant.
HOW DOES THE VACCINE WORK?
Unlike Pfizer-BioNTech and Moderna, which use messenger RNA (mRNA), the Oxford-AstraZeneca vaccine is a non-replicating viral vector, using a weakened chimpanzee cold virus as a vessel.
Scientists stripped the genes from that virus, which isnt harmful to humans, and replaced them with the spike protein gene for SARS-CoV-2.
Once injected, the vaccine shows our bodies how to produce the immune response needed to ward off future infections from the COVID-19 virus.
Non-replicating means the virus wont actually reproduce throughout the body.
WHAT ARE THE ADVANTAGES TO THIS VACCINE?
Oxford-AstraZeneca can be shipped and stored at regular refrigerator temperature, unlike Pfizer-BioNTech which requires ultra-low freezers to hold its product before its injected. Modernas vaccine is somewhere in the middle, needing a regular freezer to keep the injections at about minus 20 C.
Advertisement
This advertisement has not loaded yet, but your article continues below.
Article content
From a global vaccination standpoint, the low cost of AstraZenecas vaccine about US$4 per dose gives it another advantage. AstraZeneca, which says it aims to manufacture up to three billion doses in 2021, has pledged to make their product available at cost around the world until at least July.
The AstraZeneca vaccine forms the bulk of the stockpile acquired so far by the U.N.-backed vaccine-sharing effort known as COVAX, which aims to deploy coronavirus vaccines to people globally.
WHEN CAN WE EXPECT A ROLLOUT TO BEGIN IN CANADA?
The Canadian government has already procured 20 million doses of the Oxford-AstraZeneca vaccine and a rollout can be expected to begin shortly after the first shipments arrive in the country.
Canada will also receive up to 1.9 million doses of the AstraZeneca vaccine through COVAX by the end of June.
Prime Minister Justin Trudeau said in early February he believes most of those 20 million doses enough to inoculate 10 million people will be delivered before Canada Day.
The government has said it plans to vaccinate the majority of Canadians by September.
With files from The Associated Press
This report by The Canadian Press was first published Feb. 26, 2021.
Share this article in your social network
Posted Newsletter
Sign up to receive the daily top stories from the National Post, a division of Postmedia Network Inc.
By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300
We encountered an issue signing you up. Please try again
Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notificationsyou will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.